This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cesarone, M. R. Articles by Acerbi, G. Search for Related Content PubMed PubMed Citation Articles by Cesarone, M. R. Articles by Acerbi, G. Social Bookmarking                   What's this?

Variations in Plasma Free Radicals in Patients with Venous Hypertension with HR (Paroven, Venoruton; 0-(ß-hydroxyethyl)-rutosides): A Clinical, Prospective, Placebo-Controlled, Randomized Trial

L. Incandela, MD

M. T. DeSanctis, MD

G. Belcaro, MD, PhD

M. Dugall, MD

G. Acerbi, MD

Irvine2 Vasc Lab and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Italy; Irvine Vasc Lab, St Mary's Hospital, Imperial College, Vascular Unit, Ealing Hospital, London, UK.

The aim of this study was to demonstrate whether HR (Paroven, Venoruton; 0-(ß-hydroxyethyl)-rutosides), was effective in improving levels of plasma free radicals (PFRs) in patients with chronic venous insufficiency (CVI) and venous microangiopathy. Patients were randomized into the treatment group, which received oral HR (Ig sachets, twice daily, for 4 weeks), and a placebo group, which received comparable placebo. Below-knee Sigvaris stockings were used during the study. PFRs were measured with the D-Rom test at the finger and at a vein of the leg in an area of CVI. The mean age of included subjects was 46 years (SD 11) in the treatment group (20 patients; 6 females) and 46.4 (SD 8) in the placebo group (20 patients; 7 females). There were no differences between placebo and treatment groups at inclusion in age and sex distribution and in parameters indicating venous hypertension. The decrease of PFRs levels in the treatment group was significant, both at the finger and in the distal blood taken in areas of CVI. There there were no significant changes in the control group. In areas of venous hypertension, PFRs values were on average higher than at the finger (systemic) level (P < 0.05). In parallel with the progressive decrease in PFRs associated with treatment, the analogue score was significantly decreased at 2 (P < 0.05) and 4 weeks (P < 0.02) in the HR group. No changes were observed in the placebo group. No adverse effects were observed. In conclusion, HR treatment is effective in decreasing both the systemic and local values of PFRs and therefore may have a positive effect on the evolution of CVI.

Key Words: venous disease • varicose veins • ulcerations • HR • Paroven • Venoruton 0-(P-hydroxyethyl)-rutosides) • elastic compression • edema • veins • microangiopathy

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. R. Cesarone, G. Belcaro, and M. G. Grossi O-({beta}-Hydroxyethyl)-Rutosides (Paroven; Venoruton): New Studies, Improved Safety, and Novel Cardiovascular Applications Angiology, March 1, 2008; 59(1_suppl): 5S - 6S. [PDF]

				G. Belcaro, M. Rosaria Cesarone, A. Ledda, M. Cacchio, I. Ruffini, A. Ricci, E. Ippolito, A. Di Renzo, M. Dugall, M. Corsi, et al. O-({beta}-Hydroxyethyl)-Rutosides Systemic and Local Treatment in Chronic Venous Disease and Microangiopathy: An Independent Prospective Comparative Study Angiology, March 1, 2008; 59(1_suppl): 7S - 13S. [Abstract] [PDF]

				G. Belcaro, M. R. Cesarone, A. Ledda, M. Cacchio, I. Ruffini, A. Ricci, E. Ippolito, A. Di Renzo, M. Dugall, M. Corsi, et al. 5-Year Control and Treatment of Edema and Increased Capillary Filtration in Venous Hypertension and Diabetic Microangiopathy Using O-({beta}-Hydroxyethyl)-Rutosides: A Prospective Comparative Clinical Registry Angiology, March 1, 2008; 59(1_suppl): 14S - 20S. [Abstract] [PDF]

				U. Wollina, M. B. Abdel-Naser, and R. Mani A review of the microcirculation in skin in patients with chronic venous insufficiency: the problem and the evidence available for therapeutic options. International Journal of Lower Extremity Wounds, September 1, 2006; 5(3): 169 - 180. [Abstract] [PDF]

				M. R. Cesarone, G. Belcaro, L. Pellegrini, A. Ledda, G. Vinciguerra, A. Ricci, A. Di Renzo, I. Ruffini, G. Gizzi, E. Ippolito, et al. Venoruton(R) vs Daflon(R): Evaluation of Effects on Quality of Life in Chronic Venous Insufficiency Angiology, March 1, 2006; 57(2): 131 - 138. [Abstract] [PDF]

				M. R. Cesarone, G. Belcaro, L. Pellegrini, A. Ledda, G. Vinciguerra, A. Ricci, G. Gizzi, E. Ippolito, F. Fano, M. Dugall, et al. HR, 0-(Beta-Hydroxyethyl)-Rutosides; (Venoruton(R)): Rapid Relief of Signs/Symptoms in Chronic Venous Insufficiency and Microangiopathy: A Prospective, Controlled Study Angiology, March 1, 2005; 56(2): 165 - 172. [Abstract] [PDF]

				M. R. Cesarone, G. Belcaro, L. Pellegrini, A. Ledda, A. Di Renzo, G. Vinciguerra, A. Ricci, G. Gizzi, E. Ippolito, F. Fano, et al. HR, 0-(Beta-Hydroxyethyl)-Rutosides, in Comparison with Diosmin+Hesperidin in Chronic Venous Insufficiency and Venous Microangiopathy: An Independent, Prospective, Comparative Registry Study Angiology, January 1, 2005; 56(1): 1 - 8. [Abstract] [PDF]

				A. Ricci, I. Ruffini, M. R. Cesarone, U. Cornelli, M. Corsi, G. Belcaro, E. Ippolito, and M. Dugall Variations in Plasma Free Radicals with Topical Aescin + Essential Phospholipids Gel in Venous Hypertension: New Clinical Data Angiology, November 1, 2004; 55(6_suppl): S11 - S14. [Abstract] [PDF]